| Company Name: |
SPIRO PHARMA |
| Tel: |
|
| Email: |
eric_feng1954@126.com |
| Company Name: |
BOC Sciences |
| Tel: |
+1-631-485-4226 |
| Email: |
inquiry@bocsci.com |
|
| Product Name: | VX-166 | | Synonyms: | VX-166;WQNDPVUOABHOHK-KBPBESRZSA-N;Pentanoic acid, 3-[[(2S)-2-[3-[(methoxycarbonyl)amino]-2-oxo-1(2H)-pyridinyl]-1-oxobutyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-, (3S)- | | CAS: | 800408-39-3 | | MF: | C22H21F4N3O8 | | MW: | 531.41 | | EINECS: | | | Product Categories: | | | Mol File: | 800408-39-3.mol |  |
| | VX-166 Chemical Properties |
| | VX-166 Usage And Synthesis |
| Description | VX-166 is a broad caspase inhibitor, which can be used as a novel potential treatment for sepsis. VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. | | Uses | VX-166, a pan caspase inhibitor, can be used for the research of Non- Alcoholic Fatty Liver Disease (NAFLD), nonalcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), and other diseases involving fibrosis, steatosis, or inflammation of the liver[1]. | | References | [1] John Pollard, et al. Treatment of liver diseases with a caspase inhibitor. Patent WO2010120880A1. |
| | VX-166 Preparation Products And Raw materials |
|